Tanja de Gruijl heads the Immunotherapy and Immune monitoring Lab at the Cancer Center of the VU University medical center (VUmc) in Amsterdam, where she has been appointed Professor of Translational Tumour Immunology. Her research ranges from preclinical topics to immune monitoring of Phase I-III clinical trials. Her main line of research is the in vivo targeting and modulation of dendritic cells (DC) in tumour-draining lymph nodes and the tumour microenvironment. Further topics of research include tumour-mediated immune suppression, control of myeloid differentiation, and the targeting of NK, iNKT, and γδ-T cells. Her research has been supported by fellowships and grants from the Netherlands Organization for Scientific Research (NWO) and the Royal Dutch Cancer Society (KWF), and she is a recipient of a competitive research award of the Prostate Cancer Foundation. She is a member of the Grant Review committee of the Melanoma Research Alliance, a member of the scientific council of the Dutch Cancer Society, has chaired the Dutch Tumour Immunology Working Party, and is currently co-chair of the International Advisory Committee of the Society for the Immunotherapy of Cancer (SITC).